SphinCS GmbH

Hochheim Am Main 15 trials 9 recruiting

15 Registered trials

9 Currently recruiting

Organisation

SphinCS GmbH

Location

Hochheim Am Main, Germany

Identifier

ORG-100041064

Address

Geheimrat-Hummel-Platz 2, 65239, Germany

Departments

(private clinic)
102:
102: NA
Clinical Science for LSD
Clinical Science in LDS
Clinical Site for LSD (Lysosomal Storage Disorders)
Geheimrat-Hummel-Platz 2
n/a
SphinCS GmbH

Clinical trials at this site (15)

Search interface

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of cipaglucosidase alfa/miglustat in both E… Recruiting

2022-501095-25-01 Pediatric Subjects with Infantile-onset Pompe Disease A 5 2024-11-04
Study to evaluate the safety and efficacy of Cipaglucosidase Alfa and Miglustat in pediatric subjects with late-onset Pompe disease Recruiting

2022-502547-36-00 Late-onset Pompe disease 5 2024-03-21
A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Recruiting

2023-509715-91-00 Fabry’s disease 5 2022-05-06
A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting

2025-522146-40-00 Late-onset Pompe disease. 4 2026-02-12
1. A study to see how well nizubaglustat (AZ-3102) works in participants with GM1 gangliosidosis or GM2 gangliosidosis and how safe it is 2.… Recruiting

2024-515778-28-00 Niemann-Pick type C disease and GM1/GM2 gangliosidoses 5 2025-06-30
A study to extend treatment with JR-141 after completion of Study JR-141-GS31 Recruiting

2022-503142-41-00 Mucopolysaccharidosis type II 5 2024-05-06
An Extension study of the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Participants With Mucopolysaccharidosis Type II (MPS II)… Recruiting

2023-503837-23-00 Mucopolysaccharidosis Type II [MPS II] 5 2023-12-12
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neu… Recruiting

2024-510990-21-00 Mucopolysaccharidosis Type II [MPS II] 10 2022-11-11
Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover stu… Recruiting

2023-510278-14-00 Niemann-Pick disease type C 5 2022-06-16
Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 Ended

2024-514381-39-00 Gaucher's disease type III 5 2022-12-08
A study to evaluate the efficacy and safety of treatment with JR-141 Ended

2024-512289-33-00 Mucopolysaccharidosis type II 5 2022-08-24
A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with… Ended

2024-511990-31-00 Fabry Disease 5 2022-06-28
Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Stan… Ended

2024-518266-27-00 Niemann Pick Disease Type C1 5 2022-02-02
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease Ended

2024-513884-20-00 Fabry disease 5 2019-03-13
A dose finding study of LY3884961 in patients with Gaucher disease Halted

2022-500281-10-02 Type 1 Gaucher Disease (Peripheral/Non-neuronopathic Ma 9 2026-02-06